ImmuCell Corporation
ICCC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $6 | $6 | $8 | $8 |
| % Growth | -14.6% | -20.1% | 4.1% | – |
| Cost of Goods Sold | $3 | $4 | $5 | $5 |
| Gross Profit | $2 | $3 | $3 | $3 |
| % Margin | 42.9% | 43.7% | 41.6% | 36.5% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $1 | $1 | $1 |
| SG&A Expenses | $2 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $2 | $2 |
| Operating Income | $0 | $1 | $1 | $1 |
| % Margin | 0.4% | 8.8% | 13.9% | 8% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | $1 | $1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | $1 | $1 | $1 |
| % Margin | -2.5% | 7.8% | 17.9% | 6.6% |
| EPS | -0.02 | 0.056 | 0.16 | 0.058 |
| % Growth | -136% | -65.3% | 177.8% | – |
| EPS Diluted | -0.02 | 0.056 | 0.16 | 0.058 |
| Weighted Avg Shares Out | 9 | 9 | 9 | 9 |
| Weighted Avg Shares Out Dil | 9 | 9 | 9 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $1 | $1 | $2 | $1 |
| % Margin | 9.9% | 20.1% | 27.8% | 17% |